Related Experiment Video

Updated: Nov 16, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K

Treatment personalization in gastrointestinal neuroendocrine tumors

Chiara Borga1, Gianluca Businello1, Sabina Murgioni2

  • 1Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.

Current Treatment Options in Oncology
|February 28, 2021
PubMed
Abstract

Insights

Advances in understanding gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) molecular profiles and therapies are revolutionizing patient care. Integrating genetic and clinical data enhances tumor classification, prognosis, and personalized treatment strategies for GEP-NENs.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) represent a complex group of tumors with evolving clinical management.
  • Significant advancements in understanding the molecular basis of GEP-NENs are driving changes in diagnosis and treatment.

Purpose of the Study:

  • To highlight the impact of molecular landscape definition and novel therapeutics on GEP-NENs.
  • To emphasize the integration of genetic/epigenetic data with clinical information for improved patient outcomes.

Main Methods:

  • Review of current research on GEP-NEN molecular characterization.
  • Analysis of emerging therapeutic strategies for GEP-NENs.
  • Discussion on the integration of multi-omics data with clinical parameters.

Main Results:

  • Improved classification and prognostic stratification of GEP-NENs are achievable through molecular insights.
  • Personalized treatment approaches are becoming increasingly feasible for GEP-NEN patients.
  • The synergy between genetic/epigenetic data and clinical information is crucial for advancing GEP-NEN management.

Conclusions:

  • The evolving understanding of GEP-NENs necessitates a personalized approach to patient management.
  • Integration of molecular and clinical data is key to optimizing therapeutic strategies and patient outcomes.
  • Continued research in GEP-NEN molecular biology and therapeutics promises further improvements in care.
Keywords:
GEP-NENsImmunotherapyNETsPRRTSSAsTargeted therapies

More Related Videos

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids09:43

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids

Published on: October 14, 2019

6.7K
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

185

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
372
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
850
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K